The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents. Pharmacol Res Perspect. 2025 Oct;13(5):e70173. doi: 10.1002/prp2.70173. PMID: 40932155; PMCID: PMC12424059.
Steib A, Pohóczky K, Tóth N, Kormos V, Kun J, Kálai T, Mangel L, Mátyus P, Helyes Z.
